Pfizer shares climbed Tuesday after two punchy headlines hit the wire. FDA advisors are considering COVID-19 vaccines for ...

Pfizer closes a deal on a new Cancer drug. The stock is pacing for 4th day of gains. The Investment Committee debate the ...

Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.

According to Benzinga Pro, Pfizer's peer group average for short interest as a percentage of float is 3.60%, which means the ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

The trend is your friend is a well-known Wall Street catchphrase that often has proven to be correct. Depending on the nature ...